Irritable Bowel Syndrome (IBS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Irritable Bowel Syndrome (IBS) Market Outlook

Thelansis’s “Irritable Bowel Syndrome (IBS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Irritable Bowel Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Irritable Bowel Syndrome (IBS) Overview

Irritable bowel syndrome (IBS) is a prevalent medical condition characterized by chronic, recurrent abdominal pain, discomfort, and altered bowel habits. This condition occurs in the absence of other organic gastrointestinal (GI) diseases, and its underlying cause is still under investigation but is believed to involve multiple factors. The factors that may trigger disruptions in GI motor and sensory function include irritation from digestive byproducts, past gastroenteritis, internal irritants, gut microbiome changes, mucosal immune responses, food intolerance, and increased mucosal permeability. These underlying disruptions give rise to symptoms such as discomfort, gut motility changes, and bowel habit alterations. Genetic factors may also contribute to the development of IBS. BS can manifest with a wide array of gastrointestinal symptoms. While abdominal pain is one of the most common complaints, individuals with IBS may also experience bloating, a feeling of incomplete bowel emptying, urgency, diarrhea, straining, and constipation. The abdominal pain in IBS is typically crampy and varies in location and intensity. This pain is often associated with bowel movements, with some patients experiencing relief after bowel movements and others having worsening pain during them. Additionally, meals and emotional stress can exacerbate abdominal pain in some patients. Functional bowel disease experts established the Rome criteria to manage patients with abdominal symptoms resembling IBS. According to this classification, IBS is categorized based on the predominant stool pattern as follows:

1. IBS with predominant constipation (IBS-C): characterized by more than 25% hard stools and less than 25% loose stools.
2. IBS with predominant diarrhea (IBS-D): marked by more than 25% loose stools and less than 25% hard stools.
3. IBS with mixed bowel habits (IBS-M): characterized by more than 25% loose stools and more than 25% hard stools.
4. IBS unclassified (IBS-U): characterized by less than 25% loose stools and less than 25% hard stools.

The differential diagnosis for IBS is extensive. A comprehensive patient history, physical examination, and a few laboratory tests can help rule out conditions such as celiac disease, inflammatory bowel disease, microscopic colitis, post-cholecystectomy bile acid diarrhea, and small intestinal bacterial overgrowth (SIBO). Patients with IBS-C may also have pelvic floor dysfunction or colonic transit disorders. If treatment fails to alleviate symptoms, further evaluation may be necessary, including a rectal examination to identify patients with dyssynergia or pelvic floor issues. Management of IBS encompasses dietary adjustments, medication options, and mind-body treatments. The United States Food and Drug Administration (FDA) has approved two agents, lubiprostone and linaclotide, specifically for IBS-C treatment.

• In the United States, IBS has a prevalence ranging from 7% to 16%, with a higher incidence in women and younger individuals.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: